Current Diabetes Reports

, Volume 9, Issue 3, pp 185–187 | Cite as

ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks

  • HoWon Lee
  • Amgad N. Makaryus
  • Samy I. McFarlane
Clinical Trials Report


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Flather MD, Yusuf S, Kober L, et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575–1581.PubMedCrossRefGoogle Scholar
  2. 2.
    Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669–677.PubMedGoogle Scholar
  3. 3.
    Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253–259.Google Scholar
  4. 4.
    McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H–37H.PubMedCrossRefGoogle Scholar
  5. 5.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293–302.Google Scholar
  6. 6.
    McFarlane SI, Borer JS: Inhibition of the RAS and prevention of diabetes and CVD: mechanistic insights and lessons learned from clinical trials. Curr Diab Rep 2009, 9:1–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772–776.PubMedCrossRefGoogle Scholar
  8. 8.
    Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  9. 9.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.PubMedCrossRefGoogle Scholar
  10. 10.
    van de Wal RM, Plokker HW, Lok DJ, et al.: Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006, 106:367–372.PubMedCrossRefGoogle Scholar
  11. 11.
    Carey RM: Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 2005, 14:67–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48.PubMedGoogle Scholar
  13. 13.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.PubMedCrossRefGoogle Scholar
  14. 14.
    Lakhdar R, Al-Mallah MH, Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14:181–188.PubMedCrossRefGoogle Scholar
  15. 15.
    McDowell SE, Coleman JJ, Ferner RE: Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006, 332:1177–1181.PubMedCrossRefGoogle Scholar
  16. 16.
    Yusuf S, Teo K, Anderson C, et al.: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174–1183.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • HoWon Lee
  • Amgad N. Makaryus
  • Samy I. McFarlane

There are no affiliations available

Personalised recommendations